XML 64 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Total revenues $ 28,754 $ 27,116 $ 27,281
U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 20,591 19,438 18,884
Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 4,634 4,310 4,469
Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 3,529 3,368 3,928
Product sales      
Disaggregation of Revenue [Line Items]      
Total revenues 28,610 26,934 26,982
Product sales | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 20,508 19,377 18,716
Product sales | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 4,576 4,197 4,342
Product sales | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 3,526 3,361 3,924
Total HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 19,612 18,175 17,194
Total HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 15,918 14,848 13,820
Total HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 2,339 2,102 2,219
Total HIV | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 1,355 1,226 1,155
Biktarvy      
Disaggregation of Revenue [Line Items]      
Total revenues 13,423 11,850 10,390
Biktarvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 10,855 9,692 8,510
Biktarvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 1,509 1,253 1,103
Biktarvy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 1,060 905 777
Descovy      
Disaggregation of Revenue [Line Items]      
Total revenues 2,113 1,985 1,872
Descovy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,902 1,771 1,631
Descovy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 100 100 118
Descovy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 110 114 123
Genvoya      
Disaggregation of Revenue [Line Items]      
Total revenues 1,762 2,060 2,404
Genvoya | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,498 1,752 1,983
Genvoya | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 180 205 284
Genvoya | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 84 103 136
Odefsey      
Disaggregation of Revenue [Line Items]      
Total revenues 1,288 1,350 1,469
Odefsey | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 957 1,012 1,058
Odefsey | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 290 294 364
Odefsey | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 41 44 47
Symtuza - Revenue share      
Disaggregation of Revenue [Line Items]      
Total revenues 592 529 530
Symtuza - Revenue share | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 450 382 348
Symtuza - Revenue share | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 130 133 168
Symtuza - Revenue share | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 12 13 14
Other HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 434 401 530
Other HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 257 238 290
Other HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 129 116 182
Other HIV | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 48 47 59
Total Oncology      
Disaggregation of Revenue [Line Items]      
Total revenues 3,289 2,932 2,139
Total Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,798 1,833 1,494
Total Oncology | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 1,098 875 573
Total Oncology | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 393 224 73
Total Cell Therapy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,973 1,869 1,459
Total Cell Therapy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 896 1,055 968
Total Cell Therapy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 804 658 430
Total Cell Therapy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 274 156 60
Tecartus      
Disaggregation of Revenue [Line Items]      
Total revenues 403 370 299
Tecartus | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 234 245 221
Tecartus | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 138 110 75
Tecartus | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 31 15 3
Yescarta      
Disaggregation of Revenue [Line Items]      
Total revenues 1,570 1,498 1,160
Yescarta | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 662 811 747
Yescarta | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 666 547 355
Yescarta | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 242 140 57
Trodelvy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,315 1,063 680
Trodelvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 902 777 525
Trodelvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 294 217 143
Trodelvy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 119 68 12
Total Liver Disease      
Disaggregation of Revenue [Line Items]      
Total revenues 3,021 2,784 2,798
Total Liver Disease | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,601 1,421 1,440
Total Liver Disease | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 545 511 525
Total Liver Disease | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 876 852 833
Sofosbuvir/Velpatasvir      
Disaggregation of Revenue [Line Items]      
Total revenues 1,596 1,537 1,530
Sofosbuvir/Velpatasvir | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 922 859 844
Sofosbuvir/Velpatasvir | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 299 323 355
Sofosbuvir/Velpatasvir | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 374 355 331
Vemlidy      
Disaggregation of Revenue [Line Items]      
Total revenues 959 862 842
Vemlidy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 486 410 429
Vemlidy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 44 38 35
Vemlidy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 428 414 379
Other Liver Disease      
Disaggregation of Revenue [Line Items]      
Total revenues 467 385 426
Other Liver Disease | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 192 152 167
Other Liver Disease | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 202 150 135
Other Liver Disease | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 73 83 124
Veklury      
Disaggregation of Revenue [Line Items]      
Total revenues 1,799 2,184 3,905
Veklury | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 892 972 1,575
Veklury | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 284 408 702
Veklury | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 623 805 1,628
Total Other      
Disaggregation of Revenue [Line Items]      
Total revenues 889 859 946
Total Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 299 304 388
Total Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 310 301 323
Total Other | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 280 255 235
AmBisome      
Disaggregation of Revenue [Line Items]      
Total revenues 533 492 497
AmBisome | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 44 43 57
AmBisome | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 276 260 258
AmBisome | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 212 189 182
Other      
Disaggregation of Revenue [Line Items]      
Total revenues 356 367 449
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 255 261 331
Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 34 40 65
Other | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 68 66 53
Royalty, contract and other revenues      
Disaggregation of Revenue [Line Items]      
Total revenues 144 182 299
Royalty, contract and other revenues | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 82 62 168
Royalty, contract and other revenues | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 58 114 127
Royalty, contract and other revenues | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues $ 4 $ 7 $ 4